ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 762

Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study

Mayra Tobar Jaramillo1, Victor Santos Andrade 2, Marina Scolnik 3, Luciano Fernando Lo Giudice 4, John Jaramillo Gallego 5, Valeria Scaglioni 5 and Enrique Soriano 6, 1Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 2Rheumatology Section, Internal Medicine Service, Fundacion Valle de lili, Colombia, Cali, Valle del Cauca, Colombia, 3Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autonoma de Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 4Hospital Italiano de Buenos Aires, Buenos Aires, Ciudad Autonoma de Buenos Aires, Argentina, 5Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina, Ciudad Autónoma de Buenos Aires, Argentina, 6Rheumatology Section, Internal Medicine Service, Hospital Italiano de Buenos Aires, Argentina., Buenos Aires, Buenos Aires, Argentina

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: giant cell arteritis, polymyalgia rheumatica, statins and seasons, Vaccines

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster I: Takayasu's Arteritis & Polymyalgia Rheumatica

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: As many other rheumatologic diseases, pathogenesis of Polymyalgia Rheumatica (PMR) is
not well understood. Genetic factors seem to play a role. Some studies have suggested a seasonal
variation, indicating a possible infectious trigger; others have shown and association with statins
initiation. Our objective was to compare PMR patients with matched controls in order to identify
possible triggers in the year previous to PMR development.

Methods: PMR patients (fulfilling ACR 2012 criteria) belonging to a Health Management Organization
(HMO) of a tertiary university hospital were matched 1:1 by gender and date of birth with controls
belonging to the same HMO. Date of PMR diagnosis was considered as the index date for patients and
their correspondent control. Electronic medical records were manually reviewed and data on infections,
hospitalizations, surgeries, vaccines and starting of statins in the year previous to the index date were
recorded for both PMR patients and controls and compared between them. For PMR patients, season
where disease symptoms started was also analyzed.

Results: 169 PMR patients and 169 controls were included. 79.9 % were females. Age at PMR diagnosis
was 79.5 years (SD 6.1). No differences were found between PMR patients and controls regarding
infections, hospitalizations, vaccines, surgeries or statin initiation in the year previous to PMR diagnosis
(table 1). PMR symptoms started in summer in 50 patients (29.6%, 95% CI: 23.1-36.9), in autumn in 50
(29.6%, 95% CI: 23.1-36.9), winter in 42 (24.8%, 95% CI: 18.9-31.9) and spring in 27 (15.9%, 95% CI: 11.1-
22.4) (Table 2).

Conclusion: We didn’t find an identifiable trigger for the development of PMR when analyzing the year
previous to diagnosis comparing to matched controls. No seasonal pattern was clearly seen.


Table 1 PMR


Table 2 PMR


Disclosure: M. Tobar Jaramillo, None; V. Santos Andrade, None; M. Scolnik, Abbvie, 8, ABBVIE, 8, Bristol, 8, BRISTOL, 8, Bristol-Myers, 8, Bristol-Myers Squibb, 8, Glaxo, 8, GLAXO, 8, Lilly, 8, LILLY, 8, Pfizer, 8, PFIZER, 8, Pfizer Inc, 8, Roche, 8, ROCHE, 8; L. Lo Giudice, None; J. Jaramillo Gallego, None; V. Scaglioni, None; E. Soriano, Abbvie, 2, 5, 8, ABBVIE, 2, 5, 8, AbbVie, 2, 5, 8, Amber, 8, Amgen, 5, 8, AMGEN, 5, 8, BMS, 8, BRISTOL, 8, Bristol MS, 8, BRISTOL MYERS SQUIBB, 8, Bristol-Myers Squibb, 8, eli lilly, 5, 8, Genzyme, 8, GENZYME, 8, GLAXO, 2, Glaxo, 2, glaxosmithkline, 2, GlaxoSmithKline, 2, GSK, 2, Janssen, 8, Lilly, 5, 8, LILLY, 5, 8, Novartis, 2, 5, 8, NOVARTIS, 2, 5, 8, PFIZER, 5, 8, Pfizer, 5, 8, Pfizer Inc, 5, 8, Roche, 2, 8, ROCHE, 2, 8, Sandoz, 5, SANDOZ, 5, Sanofi, 5, SANOFI, 5, SANOPHY, 5, UCB, 8.

To cite this abstract in AMA style:

Tobar Jaramillo M, Santos Andrade V, Scolnik M, Lo Giudice L, Jaramillo Gallego J, Scaglioni V, Soriano E. Are There Any Identifiable Triggers in Polymyalgia Rheumatica? A Matched-Control Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/are-there-any-identifiable-triggers-in-polymyalgia-rheumatica-a-matched-control-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/are-there-any-identifiable-triggers-in-polymyalgia-rheumatica-a-matched-control-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology